Statements (62)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:acquisition |
gptkb:XYZ_Biotech
|
gptkbp:advertising |
Direct-to-Consumer
B2B Partnerships Digital_Marketing Mr._Alan_Brown |
gptkbp:awards |
Best Workplace 2022
|
gptkbp:budget |
2022 Report
|
gptkbp:CEO |
gptkb:John_Doe
|
gptkbp:clinicalTrials |
Ongoing
Phase IV Phase II Phase III Phase I Phase III Trials Real-World Evidence Studies CNS Disorders |
gptkbp:collaborations |
gptkb:Global_Pharma_Partners
Academic Institutions Non-Profit_Organizations International_Research_Networks |
gptkbp:community_involvement |
Health Awareness Programs
|
gptkbp:community_service |
Patient Assistance Programs
|
gptkbp:culturalHeritage |
Inclusive Hiring Practices
|
gptkbp:employees |
500
|
gptkbp:financialPerformance |
Strong Growth
|
gptkbp:focus |
Oncology
Neurology Rare Diseases |
gptkbp:founded |
2000
|
gptkbp:founder |
Jane_Smith
|
gptkbp:headquarters |
gptkb:New_Jersey
|
https://www.w3.org/2000/01/rdf-schema#label |
NS Pharmaceuticals
|
gptkbp:industry |
Pharmaceuticals
|
gptkbp:investmentFocus |
Publicly Traded
$50 million in R&D Venture_Capital_Funding |
gptkbp:market |
gptkb:Asia
gptkb:North_America Europe Global |
gptkbp:mission |
Innovate healthcare solutions.
|
gptkbp:partnerships |
Various Research Institutions
|
gptkbp:patentCitation |
Over_100_patents
|
gptkbp:products |
Prescription Drugs
|
gptkbp:regulatoryCompliance |
FDA_Approved
|
gptkbp:research |
gptkb:Dr._Emily_White
|
gptkbp:research_areas |
Cardiology
Immunology Endocrinology |
gptkbp:research_focus |
Gene Therapy
Biologics Small Molecules |
gptkbp:revenue |
$200 million
|
gptkbp:stockExchange |
NSP
|
gptkbp:subsidiary |
NS Biologics
|
gptkbp:supplyChain |
Global_Supply_Chain_Management
|
gptkbp:sustainability_initiatives |
Green Manufacturing Practices
|
gptkbp:targetMarket |
New_Drug_Launches_2023
|
gptkbp:training |
Continuous_Education_Programs
|
gptkbp:tributaryOf |
Multiple drug candidates
|
gptkbp:website |
www.nspharma.com
|